TG Therapeutics TGTX SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's SG&A?
- TG Therapeutics (TGTX) reported SG&A of $88.22M in Q1 2026.
- How has TG Therapeutics's SG&A changed year-over-year?
- TG Therapeutics's SG&A increased by 75.3% year-over-year, from $50.33M to $88.22M.
- What is the long-term trend for TG Therapeutics's SG&A?
- Over 4 years (2021 to 2025), TG Therapeutics's SG&A has grown at a 16.0% compound annual growth rate (CAGR), from $128.09M to $232.03M.
- What does SG&A mean?
- The day-to-day operating costs of running the business, excluding production costs.
- How do you interpret SG&A?
- A lower ratio of SG&A to revenue indicates high operational leverage and efficient management of overhead.
- How does SG&A compare across companies?
- Standard metric across all sectors; essential for benchmarking operational discipline against industry peers.